Allelic variations of RANKL/OPG signaling system are related to bone mineral density and in vivo gene expression.

OBJECTIVE Receptor activator of nuclear factor-kappaB ligand/osteoprotegerin (RANKL/OPG) signaling system plays a crucial role in the regulation of bone resorption. Polymorphic variations in the genes may have an influence on gene expression and bone metabolism. In the present study, we aimed to investigate the influence of RANKL/OPG allelic variations on the in vivo human gene expression of five genes, bone mineral density (BMD), and fracture incidence in Hungarian postmenopausal women. METHODS Three hundred and sixty postmenopausal women (61.6+/-7.9 years) were genotyped. All together, five single nucleotide polymorphisms (SNPs) in the two genes have been investigated. In addition, bone samples from 17 examined subjects were acquired for gene expression studies. Bone densities and fracture data have also been collected. RESULTS All two SNPs in OPG gene and three SNPs in RANKL gene showed correlation with BMD. Haplotype analysis of these genes gave similar results. The 'CCT' haplotype of RANKL promoter region, which was associated with decreased BMD, exhibited a significantly upregulated expression of RANKL mRNA, while the other haplotypes of RANKL or OPG 15 genes did not. No correlation between genetic variations and fracture data was found. CONCLUSION We have demonstrated associations between RANKL and OPG haplotypes and BMD as well as between RANKL haplotypes and in vivo RANKL expression in a Hungarian postmenopausal population. Moreover, we have found a new RANKL haplotype associating with reduced BMD and increased in vivo RANKL expression in human bone tissue.

[1]  J. Marc,et al.  Tumour necrosis factor superfamily member 11 gene promoter polymorphisms modulate promoter activity and influence bone mineral density in postmenopausal women with osteoporosis. , 2008, Journal of molecular endocrinology.

[2]  Kari Stefansson,et al.  Multiple genetic loci for bone mineral density and fractures. , 2008, The New England journal of medicine.

[3]  A Hofman,et al.  Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study , 2008, The Lancet.

[4]  T. Foroud,et al.  Association studies of ALOX5 and bone mineral density in healthy adults , 2008, Osteoporosis International.

[5]  J. Riancho,et al.  Association of the 163A/G and 1181G/C osteoprotegerin polymorphism with bone mineral density. , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[6]  V. Naganathan,et al.  Genetic Effects on Bone Loss in Peri‐ and Postmenopausal Women: A Longitudinal Twin Study , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  S. Ku,et al.  Association between osteoprotegerin (OPG), receptor activator of nuclear factor-&kgr;B (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women , 2007, Menopause.

[8]  N. Bishop,et al.  Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL , 2007, Nature Genetics.

[9]  J. Marc,et al.  Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women. , 2006, Maturitas.

[10]  Nan Hu,et al.  Decision Forest Analysis of 61 Single Nucleotide Polymorphisms in a Case-Control Study of Esophageal Cancer; a novel method , 2005, BMC Bioinformatics.

[11]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[12]  F. Ando,et al.  Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. , 2003, Molecular genetics and metabolism.

[13]  S. Teitelbaum,et al.  Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.

[14]  P. Hudler,et al.  Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[15]  E. Eriksen,et al.  Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  S. Ralston.  Genetic control of susceptibility to osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[17]  L. Hofbauer,et al.  Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology , 2001, Journal of Molecular Medicine.

[18]  Yongwon Choi,et al.  Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Sundeep Khosla,et al.  The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  L. Hofbauer,et al.  Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. , 1999, European journal of endocrinology.

[21]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[23]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[25]  S. Ortolani,et al.  Genetics of osteoporosis , 1994, Calcified Tissue International.

[26]  C. Christiansen,et al.  Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. , 1993, The American journal of medicine.

[27]  B. Riis,et al.  Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. , 1991, BMJ.

[28]  J. Sebert,et al.  [Evaluation of the calcium content of diet by frequential self-questionnaire]. , 1991, Revue du rhumatisme et des maladies osteo-articulaires.

[29]  A. Borsy,et al.  Different Gene Expression Patterns in the Bone Tissue of Aging Postmenopausal Osteoporotic and Non-osteoporotic Women , 2007, Calcified Tissue International.

[30]  F. Islam,et al.  No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women. , 2007, Bone.

[31]  T. Niu,et al.  Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men , 2005, Human Genetics.

[32]  Pak Chung Sham,et al.  Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits , 2003, Bioinform..

[33]  M. Fenger,et al.  Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios , 2003, Journal of Bone and Mineral Metabolism.

[34]  J. Aubin,et al.  Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. , 2000, Medscape women's health.